Novo Nordisk entered into a research collaboration with Ossianix

| By | Novo Nordisk, R&D
0
86

Novo Nordisk signed a research collaboration and option agreement with Ossianix to deliver therapeutic molecules in diabetes and other metabolic diseases across the Blood Brain Barrier (BBB) to the brain.

Under the terms of the agreement, Ossianix will use its patented single domain VNAR antibodies to deliver a predefined number of therapeutic agents of Novo Nordisk. Novo Nordisk will be responsible for the development and commercialization of the therapeutic products.

Ossianix will receive upfront, pre-clinical, clinical and commercial milestone payments, R&D funding, as well as product royalties from Novo Nordisk. In addition, Novo Nordisk has a buyout option for each product on pre-agreed financial terms. Financial details of the agreement are not being disclosed.

Dr. Marcus Schindler, Senior Vice President, Global Drug Discovery at Novo Nordisk, commented:

“We are excited about the opportunity to collaborate with Ossianix, who has developed a unique platform for delivery of proteins and peptides to the brain using their proprietary blood-brain-barrier shuttle technology. In combination with our experience in disease biology, the projects that we will collaborate on hold potential to make a real difference for people living with diabetes and other metabolic diseases.”

Ossianix is a pre-clinical company that develops biotherapeutic products using the highly versatile single domain VNAR antibody from the shark. The attractive biological and biophysical properties of the VNAR structure allows the rapid delivery of exquisitely high-affinity products to multiple target classes that have proven difficult or impossible by standard antibody approaches or alternative scaffolds.

The platform is also attractive for generating bispecific antibodies that can be engineered with ease to develop products with differentiated features in diseases of high unmet need. Ossianix has also developed highly innovative approaches to target specific cells and tissues such as the brain via the blood brain barrier and peripheral nerve via the neuromuscular junction. The company is headquartered in the University City Science Center in downtown Philadelphia (USA) and has research laboratories at the Stevenage Bioscience Catalyst in Stevenage, Herts (UK).

SOURCE: ossianix
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.